Building on this, a randomized phase II breast cancer study (FERGI) assessing the combination of pictilisib and the ER antagonist fulvestrant in ER-positive aromatase inhibitor-resistant advanced or metastatic breast cancer was recently reported [58]. The gene discussed is ESR1; the disease is breast cancer.